Clinical trials: Aspirin Sensitivity
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Chronic Rhinosinusitis, Aspirin Exacerbated Respiratory Disease
Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease
Aspirin-Exacerbated Respiratory Disease, or AERD, consists of aspirin sensitivity, asthma and nasal polyps. It is currently managed by chronic steroid use, multiple endoscopic sinus surgeries and/or aspirin desensitization.
- Conditions
- Chronic Rhinosinusitis, Aspirin Exacerbated Respiratory Disease, Asthma, Aspirin Sensitivity
- Trial name
- NCT01778465
- Testing
- Low salicylate diet, Normal Diet
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Aspirin Sensitivity
Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
This is a 24 week double-blind study in which subjects will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo. Xolair injections will occur every 2-4 weeks.
- Trial name
- NCT00555971
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- David Lang